IVIG for difficult gastrointestinal auto-immune nerve symptoms
Part of Digestive system, Pain clinical trials.
This trial tests intravenous immunoglobulin (IVIG), a donated antibody treatment, for people whose gastrointestinal (GI) “motor” symptoms are not improving with standard care and may be auto-immune related. If you’re eligible, IVIG could help calm the immune system and improve gut movement symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have GI motor disorder symptoms that have not improved with other treatments (“refractory”).
- Your symptoms are the kind that may be related to an auto-immune process.
- You are able to receive medication through a vein (IV) to get IVIG.
- You can likely go through the trial treatment schedule that uses IV infusions.
- Your care team believes IVIG is safe for you based on your health history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with drug-refractory gastroparesis (stomach paralysis symptoms that don’t improve with usual medicines) to better understand how symptoms and nutrition change over time. Your information may help researchers understand patterns that could improve care.
This trial is a registry, meaning it collects information about people being evaluated for problems with how the gut moves. It may help doctors better diagnose gastrointestinal motility disorders in the future.
This trial tests if IVIG (intravenous immunoglobulin, a treatment that helps the immune system) can reduce pain in people with small fiber nerve damage or sensory neuronopathy. You may qualify if you have had moderate to severe nerve pain for at least 4 weeks and other conditions have been ruled out.
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
This trial tests if IVIG (intravenous immunoglobulin, a donated blood product that helps the immune system) can improve muscle strength and reduce damage in people with anti-HMGCR immune-mediated necrotizing myopathy (a rare muscle disease where the immune system attacks muscle cells). It may help you if your muscle weakness is not too severe and you haven't tried IVIG before.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
Hear when a new Gastrointestinal Motility Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.